Assessment of In-vitro thrombolytic activity of Curcuma caesia and Coccinia grandis

Thrombotic disorders are a major global health concern, often treated with synthetic agents like streptokinase, which may lead to adverse effects such as bleeding and hypersensitivity. Exploring natural, plant-based alternatives offers a promising route for safer thrombolytic therapy. The project focuses on evaluating the clot-dissolving potential of Curcuma caesia and Coccinia grandis, both individually and synergistic effect of combined plant extract, using two methods 1st is by an in-vitro clot lysis model and another is by Prothrombine time test. Streptokinase served as the positive control, while normal saline solution served as the negative control, in an in-vitro thrombolytic model that assessed the clot lysis impact of an ethanolic extract of C. caesia rhizome and C. grandis leaf.  A thrombolytic effect of 61.4%±1.8 was seen when 75% extract of Curcuma caesia rhizome and 25% extract of Coccinia grandis leaves were employed together, in comparison to the effects of Streptokinase (64.6±4.11) as a positive control and water (7.5%±0.45) as a negative control.  The current study highlights the remarkable thrombolytic activity of C. caesia and C. grandis extracts, which are utilized to treat cardiovascular disorders.  So, it's important to find out what these extracts include that makes them thrombolytic and to monitor there In-vivo clot-solving capacity.